, Inc. (AMZN) Needs More Time: Jordan Crook

Online retail giant and tech major, Inc. (NASDAQ:AMZN) reported its second quarter earnings yesterday after market close. In the light of the selling pressure that the stock has come under today on the back of a wider than expected second quarter losses, Jordan Crook, who is a writer for TechCrunch, told CNBC on its “Earnings Central” programming segment that the “shareholders should remain patient with, Inc. (NASDAQ:AMZN) as it shapes up to “making a land-grab” in order to assure itself of future yields., Inc. (NASDAQ:AMZN)

Answering the question if investors are losing patience with, Inc. (NASDAQ:AMZN) as indicated by the share price slide seen yesterday, Crook responded: “It absolutely seems to be the case.” She went on to add that:

“It is slightly curious to me, investors for a long time have been patient with, Inc. (NASDAQ:AMZN), because this has traditionally been the go to strategy and they have continuously posted double digit revenue growth quarter over quarter for maybe 50 quarters straight.”

She went on to analyze the recent investor discontent by stating that: “it’s not to state that investors are not loving, Inc. (NASDAQ:AMZN), it’s just investors are getting a little bit antsy and wanting to see more profits and may be less spending.” Crook advocated that investors should remain patient with, Inc. (NASDAQ:AMZN) because it “has to invest in order to yield later.”

When pointed out that, Inc. (NASDAQ:AMZN) market cap had fallen behind Facebook Inc (NASDAQ:FB)’s yesterday, Crook rationalized that, Inc. (NASDAQ:AMZN) has made in the recent past huge investments to lower the margin on its hardware and has also invested close to $100 million in developing digital content, which should result in the firm being able to regain lost ground in due course.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!